EUVIMEDAtrasti EUVIMED
Vergleichsstudie

An Abbreviated Course of Therapeutic Plasma Exchange Does Not Affect Platelet Count Recovery or Durability in Patients With Immune Thrombotic Thrombocytopenic Purpura Receiving Caplacizumab

Jay S Raval, Erika Hochhaus, Grace M Lee iD

Journal of Clinical Apheresis · 2026-06 · 41 (3)

DOI: 10.1002/jca.70127 ↗

At a glance

Vergleichsstudie in Journal of Clinical Apheresis, published online on 2026-05-01. Written by Jay S Raval and 2 co-authors. Institution: Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, Vermont, USA. Major MEDLINE topics: Plasma Exchange, Single-Domain Antibodies, Purpura, Thrombotic Thrombocytopenic, Immunosuppressive Agents. 19 references.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Patients with immune thrombotic thrombocytopenic purpura (iTTP) receive daily therapeutic plasma exchange (TPE) and immunosuppression as first‐line therapies. It is recommended that TPE be performed until clinical response is achieved, typically defined as platelet counts ≥ 150 × 10 9 /L for ≥ 2 consecutive days. The anti‐von Willebrand factor agent caplacizumab is approved for patients with iTTP in combination with TPE and immunosuppression and has been shown to more rapidly normalize platelet counts and decrease exacerbations, refractoriness, and mortality. However, no studies have re‐examined endpoints for TPE cessation with concomitant caplacizumab use. We compared patients with iTTP receiving daily TPE, immunosuppression, and caplacizumab who had the typically recommended TPE treatment course versus an abbreviated course with TPE discontinued before achieving platelet counts of 150 × 10 9 /L and observed no detriment with early TPE cessation. Additional high‐quality studies re‐evaluating daily TPE cessation endpoints are needed for patients with iTTP receiving caplacizumab.

Subjects

MeSH terms (MEDLINE)

Plasma ExchangeSingle-Domain AntibodiesPurpura, Thrombotic ThrombocytopenicImmunosuppressive AgentsTime FactorsPlatelet CountFibrinolytic Agentsvon Willebrand FactorRetrospective StudiesHumansMaleFemaleAdolescentYoung AdultAdultMiddle AgedTreatment Outcome

Author keywords

ADAMTS13TTPapheresiscaplacizumab‐yhdpplasmapheresisplatelet

Substances

caplacizumabSingle-Domain AntibodiesFibrinolytic Agentsvon Willebrand FactorImmunosuppressive Agents

Authors and institutions

  • Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, Vermont, USA.
  • Department of Pathology, University of New Mexico, Albuquerque, New Mexico, USA.
  • Apheresis Center, Duke Health, Durham, North Carolina, USA.
  • Department of Medicine, Division of Hematology, Duke University Medical Center, Durham, North Carolina, USA.

ORCID profiles: Grace M Lee

Cite

APA

Raval, J. S., Hochhaus, E., & Lee, G. M. (2026). An Abbreviated Course of Therapeutic Plasma Exchange Does Not Affect Platelet Count Recovery or Durability in Patients With Immune Thrombotic Thrombocytopenic Purpura Receiving Caplacizumab. Journal of Clinical Apheresis, 41(3). https://doi.org/10.1002/jca.70127

Vancouver

Raval JS, Hochhaus E, Lee GM. An Abbreviated Course of Therapeutic Plasma Exchange Does Not Affect Platelet Count Recovery or Durability in Patients With Immune Thrombotic Thrombocytopenic Purpura Receiving Caplacizumab. Journal of Clinical Apheresis. 2026;41(3). doi:10.1002/jca.70127

BibTeX
@article{Raval2026,
  author = {Raval, Jay S and Hochhaus, Erika and Lee, Grace M},
  title = {An Abbreviated Course of Therapeutic Plasma Exchange Does Not Affect Platelet Count Recovery or Durability in Patients With Immune Thrombotic Thrombocytopenic Purpura Receiving Caplacizumab},
  journal = {Journal of Clinical Apheresis},
  year = {2026},
  volume = {41},
  number = {3},
  doi = {10.1002/jca.70127}
}
Start for free →